Search | Clinical Trials Finder

Conditions: Non Hodgkin Lymphoma, High-grade B-cell Lymphoma, Diffuse Large B Cell Lymphoma
Interventions: Cyclophosphamide, Alemtuzumab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell
Interventions: Alemtuzumab plus Fludarabine; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 27
States / cities: Birmingham, Alabama • Berkeley, California • Burbank, California + 24 more

Conditions: Lymphoplasmacytic Lymphoma, Waldenstrom's Macroglobulinemia
Interventions: Campath-1H; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years to 80 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma
Interventions: Campath, Rituximab, EPOCH; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Leukemia
Interventions: Alemtuzumab, Rituximab, Sargramostim; Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 2
States / cities: Scottsdale, Arizona • Rochester, Minnesota

Conditions: Diabetes Mellitus
Interventions: Tacrolimus, Alemtuzumab; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 60 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Hemophagocytic Lymphohistiocytosis, X-Linked Lymphoproliferative Disorders, Chediak-Higashi Syndrome, Griscelli Syndrome, Immunologic Deficiency Syndromes, Langerhans-Cell Histiocytosis
Interventions: Stem Cell Transplant, Fludarabine, Melphalan, Anti-thymocyte globulin (ATG), Campath 1H, Cyclosporin A, Mycophenolate mofetil, Intravenous immunoglobulin (IVIG); Procedure · Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 35 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2014
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Sickle Cell Anemia, Beta-thalassemia Major, Diamond-blackfan Anemia
Interventions: CD3/CD19 depleted leukocytes, CD45RA depleted leukocytes, Hydroxyurea, Rituximab, Alemtuzumab, Fludarabine, Thiotepa; Biological · Drug
Lead sponsor: Paul Szabolcs; Other
Eligibility: 5 Years to 40 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Graft vs Host Disease
Interventions: Begelomab, Conventional Second-line Treatment; Biological
Lead sponsor: Adienne SA; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 10
States / cities: Duarte, California • Westwood, Kansas • Boston, Massachusetts + 7 more

Conditions: Multiple Sclerosis (MS)
Interventions: Alemtuzumab; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Hurler's Syndrome, Maroteaux-Lamy Syndrome, Sly Syndrome, Alpha Mannosidosis, Fucosidosis, Aspartylglucosaminuria, Sphingolipidoses, Krabbe Disease, Wolman's Disease, Niemann-Pick Disease Type B, Niemann-Pick Disease, Type C
Interventions: Stem Cell Transplantation, Cyclophosphamide, Campath-1H, Busulfan; Procedure · Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 21 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: AML, ALL, CLL, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Multiple Myeloma, Aplastic Anemia, Myeloproliferative Disorder
Interventions: Cyclophosphamide; Fludarabine; Cyclosporin; CAMPATH-1H (Alemtuzumab); GM-CSF; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: Up to 65 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: T-Cell Lymphoma Relapsed, Adult T-Cell Leukemia (ATL), Peripheral T-Cell Lymphoma (PTCL), Cutaneous T Cell Lymphoma (CTCL), T-Cell Prolymphocytic Leukemia
Interventions: IL-15 plus, alemtuzumab; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
Interventions: Bendamustine, Carmustine, Etoposide, Melphalan, Cytarabine, Alemtuzumab, Autologous Stem Cell Transplantation, Allogeneic Stem Cell Transplantation, Rituximab; Drug · Biological
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: B-cell Non-Hodgkin Lymphoma (B-NHL)
Interventions: UCART20x22, CLLS52; Biological
Lead sponsor: Cellectis S.A.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: Chicago, Illinois • Boston, Massachusetts • New Brunswick, New Jersey + 1 more

Conditions: Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions: alemtuzumab, busulfan, cyclophosphamide, methotrexate, tacrolimus, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Up to 50 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions: alemtuzumab, methylprednisolone, prednisone, flow cytometry, immunologic technique, pharmacological study; Biological · Drug · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Not listed
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions: alemtuzumab, graft-versus-tumor induction therapy, rituximab, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, allogeneic bone marrow transplantation; Biological · Drug · Procedure
Lead sponsor: Northside Hospital, Inc.; Other
Eligibility: 40 Years to 72 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Aplastic Anemia
Interventions: Campath-1H, r-ATG, CsA; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 2 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Facial Injuries, Traumatic Wounds and Injuries, Craniofacial Injuries, Craniofacial Defects, Facial Transplantation, Facial Deformity
Interventions: Bone marrow cell-based therapy & 1-drug immunosuppression.; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2041
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Leukemia
Interventions: BEAM-201; Biological
Lead sponsor: Beam Therapeutics Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 10
States / cities: Stanford, California • Denver, Colorado • Chicago, Illinois + 7 more

Conditions: Sickle Cell Disease
Interventions: hydroxyurea, azathioprine, alemtuzumab, thioptepa, low dose total body irradiation and sirolimus, hydroxyurea, azathioprine, alemtuzumab, thiotepa, plerixafor, low dose total body irradiation, cyclophosphamide and sirolimus; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 2 Years to 25 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Congenital Hemolytic Anemia, Sickle Cell Disease
Interventions: Peripheral blood hematopoietic progenitor cell (PBPC) transplant, Alemtuzumab, Peripheral blood hematopoietic progenitor cell Apheresis, Sirolimus; Procedure · Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 2 Years to 80 Years
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Best Available Therapy (BAT); Procedure · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 23
States / cities: Palo Alto, California • Aurora, Colorado • Evanston, Illinois + 18 more

Search by objective public record fields.

Cyclophosphamide and Alemtuzumab In Lymphoma

Alemtuzumab/Fludarabine for Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL)

Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia

Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas

Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia

Use of Campath for Induction and Maintenance Therapy in Pancreas After Kidney Transplantation

Stem Cell Transplant for Immunologic or Histiocytic Disorders

T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias

Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD

Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis

Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism

Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders

Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)

Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma

Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma

Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant

Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer

Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia

Human Craniomaxillofacial Allotransplantation

A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)

Reduced Intensity Transplantation for Severe Sickle Cell Disease

Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)